Business Context and Reporting Period
This Form 8-K Current Report was filed by Quince Therapeutics, Inc. (QNCX) on March 28, 2023, regarding an event that occurred on March 27, 2023. The filing addresses a change in the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a director:
- Philip Low, Ph.D., a member of the Board of Directors, tendered his resignation effective immediately on March 27, 2023.
- The Company stated that Dr. Low's resignation was not the result of any disagreement with the Company, its Board, or management.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the director's departure.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Dr. Low's resignation.
- Confirm whether the Board intends to appoint a replacement director and the timeline for such an appointment.
- Review subsequent filings to ensure no undisclosed disagreements or related party transactions influenced the departure.